Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study.
Standard
Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study. / Pickar, D; Bunney, W E; Douillet, P; Sethi, B B; Sharma, M; Vartanian, M E; Lideman, R P; Naber, Dieter; Leibl, K; Yamashita, I.
In: BIOL PSYCHIAT, Vol. 25, No. 4, 4, 1989, p. 440-448.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study.
AU - Pickar, D
AU - Bunney, W E
AU - Douillet, P
AU - Sethi, B B
AU - Sharma, M
AU - Vartanian, M E
AU - Lideman, R P
AU - Naber, Dieter
AU - Leibl, K
AU - Yamashita, I
PY - 1989
Y1 - 1989
N2 - In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptic-treated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.
AB - In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptic-treated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.
M3 - SCORING: Zeitschriftenaufsatz
VL - 25
SP - 440
EP - 448
JO - BIOL PSYCHIAT
JF - BIOL PSYCHIAT
SN - 0006-3223
IS - 4
M1 - 4
ER -
